Shots:
- The US FDA has expanded the indication for Capvaxive to incl. pts aged 2–17yrs. with certain chronic medical conditions who have completed a primary pediatric pneumococcal vaccination series & remain at increased risk of pneumococcal disease
- Approval was supported by P-III (STRIDE-13) trial data, which compared Capvaxive with PPSV23 in the above-mentioned pts
- Capvaxive is designed to target 21 pneumococcal serotypes associated with invasive pneumococcal disease and pneumonia, including several serotypes not covered by currently approved pediatric pneumococcal vaccine series
Ref: Businesswire | Image: Merck | Press Release
Related News: Protillion Biosciences and Merck Enter ~$510M Drug Discovery Collaboration
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
